Quarterly Perspectives · July 2026 · 5 min read

Q2 2026 Perspective: Deployment, Pipeline and Portfolio Update

A summary of deployment pace, pipeline quality and portfolio performance for our limited partners.

Deployment

Fund II completed two investments during the quarter, in specialty chemicals and medical devices.

Aggregate portfolio revenue grew 21% year-on-year, with EBITDA margins broadly stable despite input-cost pressure.

This article is for information only and does not constitute investment advice or an offer to invest.

Formalisation, supply-chain diversification and deepening capital markets are creating a generation of institutional-grade SMEs.

How precision engineering and specialty chemical SMEs are winning global supply contracts — and what it takes to scale.

SME IPO activity remains robust, but we believe valuation discipline matters more than ever.